BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Girardi E, Sabin CA, d’Arminio Monforte A, Hogg B, Phillips AN, Gill MJ, Dabis F, Reiss P, Kirk O, Bernasconi E. Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis. 2005;41:1772-1782. [PMID: 16288403 DOI: 10.1086/498315] [Cited by in Crossref: 147] [Cited by in F6Publishing: 158] [Article Influence: 8.6] [Reference Citation Analysis]
Number Citing Articles
1 Suwanpimolkul G, Gatechompol S, Kawkitinarong K, Ueaphongsukkit T, Sophonphan J, Siriyakorn N, Jirajariyavej S, Khusuwan S, Panarat P, Wannalerdsakun S, Saetiew N, Chayangsu S, Wiwatrojanagul S, Noopetch P, Danpornprasert P, Mekviwattanawong S, Fujitnirun C, Lertpiriyasuwat C, Han WM, Kerr SJ, Ruxrungtham K, Avihingsanon A; and the HIV-TB study team. Incidence of active tuberculosis among people living with HIV receiving long-term antiretroviral therapy in high TB/HIV burden settings in Thailand: implication for tuberculosis preventive therapy. J Int AIDS Soc 2022;25:e25900. [PMID: 35384317 DOI: 10.1002/jia2.25900] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Imoto S, Suzukawa M, Takeda K, Asari I, Watanabe S, Tohma S, Nagase T, Ohta K, Teruya K, Nagai H. Evaluation of cytokine levels in response to mitogen among HIV-1-infected blood cells and their relationships to the number of T cells. Cytokine 2022;153:155840. [PMID: 35276635 DOI: 10.1016/j.cyto.2022.155840] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Sergevnin VI, Tukacheva OV. Manifestations of epidemic process of tuberculosis among HIV-infected patients and dependence of infection frequency on immunodeficiency level and HIV viral load. Perm Medical Journal 2022;39:85-93. [DOI: 10.17816/pmj39185-93] [Reference Citation Analysis]
4 Alemu A, Bitew ZW, Yesuf A, Zerihun B, Getu M. The Effect of Long-Term HAART on the Incidence of Tuberculosis Among People Living with HIV in Addis Ababa, Ethiopia: A Matched Nested Case-Control Study. Infect Drug Resist 2021;14:5189-98. [PMID: 34908853 DOI: 10.2147/IDR.S345080] [Reference Citation Analysis]
5 Dumitrescu F, Pisoschi CG, Pădureanu V, Stoian AC, Dragonu L, Giubelan L. The Role of QuantiFERON-TB Gold Plus in Mycobacterium Tuberculosis Detection in a Severe HIV Immunocompromised Patient-Case Report. Pathogens 2021;10:1523. [PMID: 34832677 DOI: 10.3390/pathogens10111523] [Reference Citation Analysis]
6 Darraj MA, Abdulhaq AA, Yassin A, Mubarki S, Shalaby HM, Keynan Y, Ghailan KY, Al-Mekhlafi HM. Tuberculosis among people living with HIV/AIDS in Jazan Region, Southwestern Saudi Arabia. J Infect Public Health 2021;14:1571-7. [PMID: 34656963 DOI: 10.1016/j.jiph.2021.09.009] [Reference Citation Analysis]
7 Gies V, Dieudonné Y, Morel F, Sougakoff W, Carapito R, Martin A, Weingertner N, Jacquel L, Hubele F, Kuhnert C, Jung S, Schramm F, Boyer P, Hansmann Y, Danion F, Korganow AS, Guffroy A. Case Report: Acquired Disseminated BCG in the Context of a Delayed Immune Reconstitution After Hematological Malignancy. Front Immunol 2021;12:696268. [PMID: 34413849 DOI: 10.3389/fimmu.2021.696268] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Tiruneh F, Deyas Y. How Far Does Highly Active Antiretroviral Treatment Reduce TB Incidence among Children? A Marginal Structural Modeling Analysis, Southwest Ethiopia. Ethiop J Health Sci 2020;30:653-60. [PMID: 33911825 DOI: 10.4314/ejhs.v30i5.3] [Reference Citation Analysis]
9 Arora U, Garg P, Agarwal S, Nischal N, Shalimar, Wig N. Complexities in the treatment of coinfection with HIV, hepatitis B, hepatitis C, and tuberculosis. Lancet Infect Dis 2021;21:e399-406. [PMID: 34023004 DOI: 10.1016/S1473-3099(20)30765-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Namdev P, Patel S, Sparling B, Garg A. Monocytic-Myeloid Derived Suppressor Cells of HIV-Infected Individuals With Viral Suppression Exhibit Suppressed Innate Immunity to Mycobacterium tuberculosis. Front Immunol 2021;12:647019. [PMID: 33995365 DOI: 10.3389/fimmu.2021.647019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Tiruneh F, Deyas Y. Effect of highly active antiretroviral treatment on TB incidence among HIV infected children and their clinical profile, retrospective cohort study, South West Ethiopia. Sci Rep 2020;10:21468. [PMID: 33293656 DOI: 10.1038/s41598-020-78466-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Meziane O, Salahuddin S, Pham TNQ, Farnos O, Pagliuzza A, Olivenstein R, Thomson E, Alexandrova Y, Orlova M, Schurr E, Ancuta P, Haddad É, Chomont N, Cohen EA, Jenabian MA, Costiniuk CT. HIV Infection and Persistence in Pulmonary Mucosal Double Negative T Cells In Vivo. J Virol 2020;94:e01788-20. [PMID: 32967958 DOI: 10.1128/JVI.01788-20] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
13 Bisognin F, Lombardi G, Re MC, Dal Monte P. QuantiFERON-TB Gold Plus with Chemiluminescence Immunoassay: Do We Need a Higher Cutoff? J Clin Microbiol 2020;58:e00780-20. [PMID: 32759352 DOI: 10.1128/JCM.00780-20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Tchakounte Youngui B, Coffie P, Messou E, Poda A, Fortes Deguenonvo L, Hawerlander D, Minga A, Balestre E, Dabis F, Marcy O. Incidence of Tuberculosis During the First Year of Antiretroviral Treatment in West African HIV-Infected Adults. Open Forum Infect Dis 2020;7:ofaa203. [PMID: 32607387 DOI: 10.1093/ofid/ofaa203] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Nugus GG, Irena ME. Determinants of Active Tuberculosis Occurrences after ART Initiation among Adult HIV-Positive Clients in West Showa Zone Public Hospitals, Ethiopia: A Case-Control Study. Advances in Public Health 2020;2020:1-8. [DOI: 10.1155/2020/8237928] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
16 Wolday D, Kebede Y, Legesse D, Siraj DS, McBride JA, Kirsch MJ, Striker R. Role of CD4/CD8 ratio on the incidence of tuberculosis in HIV-infected patients on antiretroviral therapy followed up for more than a decade. PLoS One 2020;15:e0233049. [PMID: 32442166 DOI: 10.1371/journal.pone.0233049] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
17 Geremew D, Melku M, Endalamaw A, Woldu B, Fasil A, Negash M, Baynes HW, Geremew H, Teklu T, Deressa T, Tessema B, Sack U. Tuberculosis and its association with CD4+ T cell count among adult HIV positive patients in Ethiopian settings: a systematic review and meta-analysis. BMC Infect Dis 2020;20:325. [PMID: 32380957 DOI: 10.1186/s12879-020-05040-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
18 Petruccioli E, Chiacchio T, Navarra A, Vanini V, Cuzzi G, Cimaglia C, Codecasa LR, Pinnetti C, Riccardi N, Palmieri F, Antinori A, Goletti D. Effect of HIV-infection on QuantiFERON-plus accuracy in patients with active tuberculosis and latent infection. J Infect 2020;80:536-46. [PMID: 32097688 DOI: 10.1016/j.jinf.2020.02.009] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
19 Takarinda KC, Choto R, Sandy C, Apollo T, Duri C, Dube F, Mpofu A, Timire C, Mugurungi O, Makaza V, Tapera R, Harries AD. How well does the process of screening and diagnosis work for HIV-infected persons identified with presumptive tuberculosis who are attending HIV care and treatment clinics in Harare city, Zimbabwe? Trans R Soc Trop Med Hyg 2018;112:450-7. [PMID: 30032237 DOI: 10.1093/trstmh/try073] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
20 McLaren ZM, Sharp A, Brouwer E, Nanoo A. The Impact of Anti-Retroviral Therapy on Tuberculosis Detection at the National Level in South Africa. Am J Trop Med Hyg 2018;99:1407-14. [PMID: 30277200 DOI: 10.4269/ajtmh.17-0530] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 du Bruyn E, Peton N, Esmail H, Howlett PJ, Coussens AK, Wilkinson RJ. Recent progress in understanding immune activation in the pathogenesis in HIV-tuberculosis co-infection. Curr Opin HIV AIDS 2018;13:455-61. [PMID: 30286038 DOI: 10.1097/COH.0000000000000501] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
22 Yen YF, Chen M, Jen IA, Chuang PH, Lee CY, Lin SI, Chen YA. Short- and Long-term Risks of Highly Active Antiretroviral Treatment with Incident Opportunistic Infections among People Living with HIV/AIDS. Sci Rep 2019;9:3476. [PMID: 30837537 DOI: 10.1038/s41598-019-39665-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
23 Amelio P, Portevin D, Hella J, Reither K, Kamwela L, Lweno O, Tumbo A, Geoffrey L, Ohmiti K, Ding S, Pantaleo G, Daubenberger C, Perreau M. HIV Infection Functionally Impairs Mycobacterium tuberculosis-Specific CD4 and CD8 T-Cell Responses. J Virol 2019;93:e01728-18. [PMID: 30541853 DOI: 10.1128/JVI.01728-18] [Cited by in Crossref: 26] [Cited by in F6Publishing: 34] [Article Influence: 8.7] [Reference Citation Analysis]
24 Singh SK, Larsson M, Schön T, Stendahl O, Blomgran R. HIV Interferes with the Dendritic Cell-T Cell Axis of Macrophage Activation by Shifting Mycobacterium tuberculosis-Specific CD4 T Cells into a Dysfunctional Phenotype. J Immunol 2019;202:816-26. [PMID: 30593540 DOI: 10.4049/jimmunol.1800523] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
25 Falana A, Akpojiyovwi V, Sey E, Akpaffiong A, Agumbah O, Chienye S, Banks J, Jones E, Spooner KK, Salemi JL, Olaleye OA, Onyiego SD, Salihu HM. Hospital length of stay and cost burden of HIV, tuberculosis, and HIV-tuberculosis coinfection among pregnant women in the United States. Am J Infect Control 2018;46:564-70. [PMID: 29108662 DOI: 10.1016/j.ajic.2017.09.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
26 Yen YF, Jen IA, Chuang PH, Chen M, Lan YC, Lee CY, Arthur Chen YM. Association of highly active antiretroviral treatment with incident tuberculosis in people living with HIV/AIDS. Ann Epidemiol 2018;28:886-892.e3. [PMID: 29656849 DOI: 10.1016/j.annepidem.2018.03.011] [Reference Citation Analysis]
27 Sohn S, Shi HJ, Wang SH, Lee SK, Park SY, Lee JS, Eom JS. Mycobacterium avium Complex Infection-Related Immune Reconstitution Inflammatory Syndrome Mimicking Lymphoma in an Human Immunodeficiency Virus-Infected Patient. Infect Chemother 2018;50:350-6. [PMID: 30600659 DOI: 10.3947/ic.2018.50.4.350] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
28 Fernandez D, Salami I, Davis J, Mbah F, Kazeem A, Ash A, Babino J, Carter L, Salemi JL, Spooner KK, Olaleye OA, Salihu HM. HIV-TB Coinfection among 57 Million Pregnant Women, Obstetric Complications, Alcohol Use, Drug Abuse, and Depression. J Pregnancy 2018;2018:5896901. [PMID: 29507814 DOI: 10.1155/2018/5896901] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
29 Fenner L, Atkinson A, Boulle A, Fox MP, Prozesky H, Zürcher K, Ballif M, Furrer H, Zwahlen M, Davies MA, Egger M; International Epidemiology Database to Evaluate AIDS in Southern Africa (IeDEA-SA). HIV viral load as an independent risk factor for tuberculosis in South Africa: collaborative analysis of cohort studies. J Int AIDS Soc 2017;20:21327. [PMID: 28691438 DOI: 10.7448/IAS.20.1.21327] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
30 Winter JR, Stagg HR, Smith CJ, Brown AE, Lalor MK, Lipman M, Pozniak A, Skingsley A, Kirwan P, Yin Z, Thomas HL, Delpech V, Abubakar I. Injecting drug use predicts active tuberculosis in a national cohort of people living with HIV. AIDS 2017;31:2403-13. [PMID: 28857827 DOI: 10.1097/QAD.0000000000001635] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
31 Maniewski U, Payen MC, Delforge M, De Wit S. Is systematic screening and treatment for latent tuberculosis infection in HIV patients useful in a low endemic setting? Acta Clin Belg 2017;72:238-41. [PMID: 27686180 DOI: 10.1080/17843286.2016.1237696] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
32 Day CL, Abrahams DA, Harris LD, van Rooyen M, Stone L, de Kock M, Hanekom WA. HIV-1 Infection Is Associated with Depletion and Functional Impairment of Mycobacterium tuberculosis-Specific CD4 T Cells in Individuals with Latent Tuberculosis Infection. J Immunol 2017;199:2069-80. [PMID: 28760884 DOI: 10.4049/jimmunol.1700558] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 6.4] [Reference Citation Analysis]
33 Pettit AC, Mendes A, Jenkins C, Napravnik S, Freeman A, Shepherd BE, Dowdy D, Gill J, Rachlis A, Moore R, Sterling TR; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) investigators of International epidemiologic Databases to Evaluate AIDS (IeDEA). Timing of Antiretroviral Treatment, Immunovirologic Status, and TB Risk: Implications for Testing and Treatment. J Acquir Immune Defic Syndr 2016;72:572-8. [PMID: 27049511 DOI: 10.1097/QAI.0000000000001018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
34 Seu L, Mobley JA, Goepfert PA. CD4+ T cells from HIV-1 patients with impaired Th1 effector responses to Mycobacterium tuberculosis exhibit diminished histone and nucleoprotein signatures. Clin Immunol 2017;181:16-23. [PMID: 28552470 DOI: 10.1016/j.clim.2017.05.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
35 Cui Z, Lin M, Nie S, Lan R. Risk factors associated with Tuberculosis (TB) among people living with HIV/AIDS: A pair-matched case-control study in Guangxi, China. PLoS One 2017;12:e0173976. [PMID: 28358846 DOI: 10.1371/journal.pone.0173976] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
36 Pathmanathan I, Dokubo EK, Shiraishi RW, Agolory SG, Auld AF, Onotu D, Odafe S, Dalhatu I, Abiri O, Debem HC, Bashorun A, Ellerbrock T. Incidence and predictors of tuberculosis among HIV-infected adults after initiation of antiretroviral therapy in Nigeria, 2004-2012. PLoS One 2017;12:e0173309. [PMID: 28282390 DOI: 10.1371/journal.pone.0173309] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
37 Ewig S. Pneumonie unter HIV-Infektion. Pneumonie 2017. [DOI: 10.1007/978-3-662-45996-6_66-1] [Reference Citation Analysis]
38 Álvaro-Meca A, Díaz A, de Miguel Díez J, Resino R, Resino S. Environmental Factors Related to Pulmonary Tuberculosis in HIV-Infected Patients in the Combined Antiretroviral Therapy (cART) Era. PLoS One 2016;11:e0165944. [PMID: 27812194 DOI: 10.1371/journal.pone.0165944] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
39 Eldholm V, Rieux A, Monteserin J, Lopez JM, Palmero D, Lopez B, Ritacco V, Didelot X, Balloux F. Impact of HIV co-infection on the evolution and transmission of multidrug-resistant tuberculosis. Elife 2016;5:e16644. [PMID: 27502557 DOI: 10.7554/eLife.16644] [Cited by in Crossref: 35] [Cited by in F6Publishing: 41] [Article Influence: 5.8] [Reference Citation Analysis]
40 Canaday DH, Toossi Z. Granulomatous Responses in HIV and Mycobacterium tuberculosis Coinfection. J Infect Dis 2016;214:1292-3. [DOI: 10.1093/infdis/jiw314] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
41 Kamarulzaman A, Reid SE, Schwitters A, Wiessing L, El-Bassel N, Dolan K, Moazen B, Wirtz AL, Verster A, Altice FL. Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners. Lancet 2016;388:1115-26. [PMID: 27427456 DOI: 10.1016/S0140-6736(16)30769-3] [Cited by in Crossref: 120] [Cited by in F6Publishing: 126] [Article Influence: 20.0] [Reference Citation Analysis]
42 Manavi K, Hodson J. An observational study on the incidence of tuberculosis among a cohort of HIV infected adults in a setting with low prevalence of tuberculosis. HIV Clinical Trials 2016;17:181-8. [DOI: 10.1080/15284336.2016.1201321] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
43 Anígilájé EA, Aderibigbe SA, Adeoti AO, Nweke NO. Tuberculosis, before and after Antiretroviral Therapy among HIV-Infected Children in Nigeria: What Are the Risk Factors? PLoS One 2016;11:e0156177. [PMID: 27232185 DOI: 10.1371/journal.pone.0156177] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
44 Iroezindu MO, Ofondu EO, Mbata GC, van Wyk B, Hausler HP, Dh A, Lynen L, Hopewell PC. Factors Associated with Prevalent Tuberculosis Among Patients Receiving Highly Active Antiretroviral Therapy in a Nigerian Tertiary Hospital. Ann Med Health Sci Res 2016;6:120-8. [PMID: 27213096 DOI: 10.4103/2141-9248.181837] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
45 Smith T, Samandari T, Abimbola T, Marston B, Sangrujee N. Implementation and Operational Research: Cost-Effectiveness of Antiretroviral Therapy and Isoniazid Prophylaxis to Reduce Tuberculosis and Death in People Living With HIV in Botswana. J Acquir Immune Defic Syndr 2015;70:e84-93. [PMID: 26258564 DOI: 10.1097/QAI.0000000000000783] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
46 Ayele HT, Mourik MS, Debray TP, Bonten MJ. Isoniazid Prophylactic Therapy for the Prevention of Tuberculosis in HIV Infected Adults: A Systematic Review and Meta-Analysis of Randomized Trials. PLoS One 2015;10:e0142290. [PMID: 26551023 DOI: 10.1371/journal.pone.0142290] [Cited by in Crossref: 60] [Cited by in F6Publishing: 65] [Article Influence: 8.6] [Reference Citation Analysis]
47 Chang CA, Meloni ST, Eisen G, Chaplin B, Akande P, Okonkwo P, Rawizza HE, Tchetgen Tchetgen E, Kanki PJ. Tuberculosis Incidence and Risk Factors Among Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy in a Large HIV Program in Nigeria. Open Forum Infect Dis 2015;2:ofv154. [PMID: 26613097 DOI: 10.1093/ofid/ofv154] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
48 Lee SS, Lin HH, Tsai HC, Su IJ, Yang CH, Sun HY, Hung CC, Sy CL, Wu KS, Chen JK, Chen YS, Fang CT. A Clinical Algorithm to Identify HIV Patients at High Risk for Incident Active Tuberculosis: A Prospective 5-Year Cohort Study. PLoS One 2015;10:e0135801. [PMID: 26280669 DOI: 10.1371/journal.pone.0135801] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
49 Musa BM, Musa B, Muhammed H, Ibrahim N, Musa AG. Incidence of tuberculosis and immunological profile of TB/HIV co-infected patients in Nigeria. Ann Thorac Med 2015;10:185-92. [PMID: 26229561 DOI: 10.4103/1817-1737.160838] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
50 Riou C, Tanko RF, Soares AP, Masson L, Werner L, Garrett NJ, Samsunder N, Karim QA, Karim SSA, Burgers WA. Restoration of CD4+ Responses to Copathogens in HIV-Infected Individuals on Antiretroviral Therapy Is Dependent on T Cell Memory Phenotype. J Immunol 2015;195:2273-81. [PMID: 26195814 DOI: 10.4049/jimmunol.1500803] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
51 Liu E, Makubi A, Drain P, Spiegelman D, Sando D, Li N, Chalamilla G, Sudfeld CR, Hertzmark E, Fawzi WW. Tuberculosis incidence rate and risk factors among HIV-infected adults with access to antiretroviral therapy. AIDS 2015;29:1391-9. [PMID: 26091295 DOI: 10.1097/QAD.0000000000000705] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 7.6] [Reference Citation Analysis]
52 Ablanedo-Terrazas Y, Alvarado-de la Barrera C, Ruiz-Cruz M, Reyes-Terán G. Mycobacterial cervicofacial lymphadenitis in human immunodeficiency virus-infected individuals after antiretroviral therapy initiation. Laryngoscope 2015;125:2498-502. [PMID: 26152748 DOI: 10.1002/lary.25470] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
53 Saha R, Saha I. Risk of tuberculosis among HAART receiving HIV patients attending an ART centre of West Bengal, India: a prospective cohort study. J Community Health 2014;39:935-42. [PMID: 24996655 DOI: 10.1007/s10900-014-9907-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
54 Gupta RK, Rice B, Brown AE, Thomas HL, Zenner D, Anderson L, Pedrazzoli D, Pozniak A, Abubakar I, Delpech V, Lipman M. Does antiretroviral therapy reduce HIV-associated tuberculosis incidence to background rates? A national observational cohort study from England, Wales, and Northern Ireland. Lancet HIV 2015;2:e243-51. [PMID: 26423197 DOI: 10.1016/S2352-3018(15)00063-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
55 Akolo C, Bada F, Okpokoro E, Nwanne O, Iziduh S, Usoroh E, Ali T, Ibeziako V, Oladimeji O, Odo M. Debunking the myths perpetuating low implementation of isoniazid preventive therapy amongst human immunodeficiency virus-infected persons. World J Virology 2015; 4(2): 105-112 [PMID: 25964875 DOI: 10.5501/wjv.v4.i2.105] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
56 Haraka F, Glass TR, Sikalengo G, Gamell A, Ntamatungiro A, Hatz C, Tanner M, Furrer H, Battegay M, Letang E. A Bundle of Services Increased Ascertainment of Tuberculosis among HIV-Infected Individuals Enrolled in a HIV Cohort in Rural Sub-Saharan Africa. PLoS One 2015;10:e0123275. [PMID: 25897491 DOI: 10.1371/journal.pone.0123275] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
57 Meijerink H, Wisaksana R, Lestari M, Meilana I, Chaidir L, van der Ven AJ, Alisjahbana B, van Crevel R. Active and latent tuberculosis among HIV-positive injecting drug users in Indonesia. J Int AIDS Soc 2015;18:19317. [PMID: 25690530 DOI: 10.7448/IAS.18.1.19317] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
58 Levine DP, Brown PD. Infections in Injection Drug Users. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases 2015. [DOI: 10.1016/b978-1-4557-4801-3.00317-9] [Reference Citation Analysis]
59 Klein PW, Harris TG, Leone PA, Pettifor AE. HIV testing of tuberculosis patients by public and private providers in New York City. J Community Health 2014;39:494-502. [PMID: 24173530 DOI: 10.1007/s10900-013-9783-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
60 Chiacchio T, Petruccioli E, Vanini V, Cuzzi G, Pinnetti C, Sampaolesi A, Antinori A, Girardi E, Goletti D. Polyfunctional T-cells and effector memory phenotype are associated with active TB in HIV-infected patients. Journal of Infection 2014;69:533-45. [DOI: 10.1016/j.jinf.2014.06.009] [Cited by in Crossref: 76] [Cited by in F6Publishing: 73] [Article Influence: 9.5] [Reference Citation Analysis]
61 Gutsfeld C, Olaru ID, Vollrath O, Lange C. Attitudes about tuberculosis prevention in the elimination phase: a survey among physicians in Germany. PLoS One 2014;9:e112681. [PMID: 25393241 DOI: 10.1371/journal.pone.0112681] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
62 Kufa T, Mabuto T, Muchiri E, Charalambous S, Rosillon D, Churchyard G, Harris RC. Incidence of HIV-associated tuberculosis among individuals taking combination antiretroviral therapy: a systematic review and meta-analysis. PLoS One 2014;9:e111209. [PMID: 25393281 DOI: 10.1371/journal.pone.0111209] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
63 Long R, Niruban S, Heffernan C, Cooper R, Fisher D, Ahmed R, Egedahl ML, Fur R. A 10-year population based study of 'opt-out' HIV testing of tuberculosis patients in Alberta, Canada: national implications. PLoS One 2014;9:e98993. [PMID: 24911262 DOI: 10.1371/journal.pone.0098993] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
64 References. HIV and the Pathogenesis of AIDS 2014. [DOI: 10.1128/9781555815653.refs] [Reference Citation Analysis]
65 Naidoo K, Karim QA, Bhushan A, Naidoo K, Yende-Zuma N, McHunu PK, Frohlich J, Karim F, Upfold M, Kocheleff P, Abdool Karim SS. High rates of tuberculosis in patients accessing HAART in rural South Africa. J Acquir Immune Defic Syndr 2014;65:438-46. [PMID: 24256629 DOI: 10.1097/QAI.0000000000000060] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
66 Karo B, Haas W, Kollan C, Gunsenheimer-Bartmeyer B, Hamouda O, Fiebig L; German ClinSurv HIV Study Group. Tuberculosis among people living with HIV/AIDS in the German ClinSurv HIV Cohort: long-term incidence and risk factors. BMC Infect Dis 2014;14:148. [PMID: 24646042 DOI: 10.1186/1471-2334-14-148] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
67 Munthali L, Khan PY, Mwaungulu NJ, Chilongo F, Floyd S, Kayange M, Glynn JR, French N, Crampin AC. The effect of HIV and antiretroviral therapy on characteristics of pulmonary tuberculosis in northern Malawi: a cross-sectional study. BMC Infect Dis 2014;14:107. [PMID: 24568242 DOI: 10.1186/1471-2334-14-107] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
68 Mu W, Zhao Y, Sun X, Ma Y, Yu L, Liu X, Zhao D, Dou Z, Fang H, Zhang F. Incidence and associated factors of pulmonary tuberculosis in HIV-infected children after highly active antiretroviral therapy (HAART) in China: a retrospective study. AIDS Care 2014;26:1127-35. [PMID: 24512621 DOI: 10.1080/09540121.2014.882492] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
69 Alvaro-Meca A, Rodríguez-Gijón L, Díaz A, Gil A, Resino S. Incidence and mortality of tuberculosis disease in Spain between 1997 and 2010: impact of human immunodeficiency virus (HIV) status. J Infect 2014;68:355-62. [PMID: 24365787 DOI: 10.1016/j.jinf.2013.12.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
70 Sudjaritruk T, Maleesatharn A, Prasitsuebsai W, Fong SM, Le NO, Le TT, Lumbiganon P, Kumarasamy N, Kurniati N, Hansudewechakul R, Yusoff NK, Razali KA, Kariminia A, Sohn AH, Sirisanthana V; TREAT Asia Pediatric HIV Observational Database. Prevalence, characteristics, management, and outcome of pulmonary tuberculosis in HIV-infected children in the TREAT Asia pediatric HIV Observational Database (TApHOD). AIDS Patient Care STDS 2013;27:649-56. [PMID: 24206012 DOI: 10.1089/apc.2013.0236] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
71 Mor Z, Lidji M, Cedar N, Grotto I, Chemtob D. Tuberculosis incidence in HIV/AIDS patients in Israel, 1983-2010. PLoS One 2013;8:e79691. [PMID: 24278157 DOI: 10.1371/journal.pone.0079691] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
72 Saharia KK, Koup RA. T cell susceptibility to HIV influences outcome of opportunistic infections. Cell 2013;155:505-14. [PMID: 24243010 DOI: 10.1016/j.cell.2013.09.045] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
73 Han SH, Zhou J, Lee MP, Zhao H, Chen YM, Kumarasamy N, Pujari S, Lee C, Omar SF, Ditangco R, Phanuphak N, Kiertiburanakul S, Chaiwarith R, Merati TP, Yunihastuti E, Tanuma J, Saphonn V, Sohn AH, Choi JY; TREAT Asia HIV Observational Database. Prognostic significance of the interval between the initiation of antiretroviral therapy and the initiation of anti-tuberculosis treatment in HIV/tuberculosis-coinfected patients: results from the TREAT Asia HIV Observational Database. HIV Med 2014;15:77-85. [PMID: 23980589 DOI: 10.1111/hiv.12073] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
74 Akanbi MO, Achenbach CJ, Feinglass J, Taiwo B, Onu A, Pho MT, Agbaji O, Kanki P, Murphy RL. Tuberculosis after one year of combination antiretroviral therapy in Nigeria: a retrospective cohort study. AIDS Res Hum Retroviruses 2013;29:931-7. [PMID: 23316724 DOI: 10.1089/AID.2012.0231] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
75 May MT, Ingle SM, Costagliola D, Justice AC, de Wolf F, Cavassini M, D'Arminio Monforte A, Casabona J, Hogg RS, Mocroft A, Lampe FC, Dabis F, Fätkenheuer G, Sterling TR, del Amo J, Gill MJ, Crane HM, Saag MS, Guest J, Brodt HR, Sterne JA; Antiretroviral Cohort Collaboration. Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). Int J Epidemiol 2014;43:691-702. [PMID: 23599235 DOI: 10.1093/ije/dyt010] [Cited by in Crossref: 46] [Cited by in F6Publishing: 52] [Article Influence: 5.1] [Reference Citation Analysis]
76 Dierberg KL, Chaisson RE. Human immunodeficiency virus-associated tuberculosis: update on prevention and treatment. Clin Chest Med 2013;34:217-28. [PMID: 23702172 DOI: 10.1016/j.ccm.2013.02.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
77 Hwang JH, Choe PG, Kim NH, Bang JH, Song KH, Park WB, Kim ES, Park SW, Kim HB, Kim NJ, Oh MD, Choe KW. Incidence and risk factors of tuberculosis in patients with human immunodeficiency virus infection. J Korean Med Sci 2013;28:374-7. [PMID: 23486534 DOI: 10.3346/jkms.2013.28.3.374] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
78 Auld AF, Mbofana F, Shiraishi RW, Alfredo C, Sanchez M, Ellerbrock TV, Nelson LJ. Incidence and determinants of tuberculosis among adults initiating antiretroviral therapy--Mozambique, 2004-2008. PLoS One 2013;8:e54665. [PMID: 23349948 DOI: 10.1371/journal.pone.0054665] [Cited by in Crossref: 23] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
79 Grenfell P, Baptista Leite R, Garfein R, de Lussigny S, Platt L, Rhodes T. Tuberculosis, injecting drug use and integrated HIV-TB care: a review of the literature. Drug Alcohol Depend 2013;129:180-209. [PMID: 23306095 DOI: 10.1016/j.drugalcdep.2012.11.013] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
80 Agodokpessi G, Ade G, Ade S, Wachinou AP, Affolabi D, Anagonou S, Gninafon M. Management of tuberculosis and HIV co-infection in Cotonou, Benin. Med Mal Infect 2012;42:561-6. [PMID: 23044083 DOI: 10.1016/j.medmal.2012.07.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
81 Suthar AB, Lawn SD, del Amo J, Getahun H, Dye C, Sculier D, Sterling TR, Chaisson RE, Williams BG, Harries AD, Granich RM. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med 2012;9:e1001270. [PMID: 22911011 DOI: 10.1371/journal.pmed.1001270] [Cited by in Crossref: 239] [Cited by in F6Publishing: 262] [Article Influence: 23.9] [Reference Citation Analysis]
82 Kassa A, Teka A, Shewaamare A, Jerene D. Incidence of tuberculosis and early mortality in a large cohort of HIV infected patients receiving antiretroviral therapy in a tertiary hospital in Addis Ababa, Ethiopia. Trans R Soc Trop Med Hyg 2012;106:363-70. [PMID: 22521216 DOI: 10.1016/j.trstmh.2012.03.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
83 Estébanez-muñoz M, Soto-abánades CI, Ríos-blanco JJ, Arribas JR. Updating Our Understanding of Pulmonary Disease Associated With HIV Infection. Archivos de Bronconeumología (English Edition) 2012;48:126-32. [DOI: 10.1016/j.arbr.2012.02.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
84 Girardi E, Palmieri F, Angeletti C, Vanacore P, Matteelli A, Gori A, Carbonara S, Ippolito G. Impact of previous ART and of ART initiation on outcome of HIV-associated tuberculosis. Clin Dev Immunol 2012;2012:931325. [PMID: 22489253 DOI: 10.1155/2012/931325] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
85 Wood R, Lawn SD. Antiretroviral treatment as prevention: impact of the 'test and treat' strategy on the tuberculosis epidemic. Curr HIV Res 2011;9:383-92. [PMID: 21999773 DOI: 10.2174/157016211798038524] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
86 Valin N, Chouaïd C. La tuberculose en France en 2010 : épidémiologie, clinique et microbiologie. Revue des Maladies Respiratoires 2012;29:267-76. [DOI: 10.1016/j.rmr.2011.07.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
87 Estébanez-Muñoz M, Soto-Abánades CI, Ríos-Blanco JJ, Arribas JR. Updating our understanding of pulmonary disease associated with HIV infection. Arch Bronconeumol 2012;48:126-32. [PMID: 22257776 DOI: 10.1016/j.arbres.2011.12.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
88 Bushra AW, Zeynudin A, Dejene T, Wolde M, Sudhakar M. Risk factors for tuberculosis after highly active antiretroviral treatment (HAART) initiation among HIV patients: A systematic review. JBI Library of Systematic Reviews 2012;10:3561-3595. [DOI: 10.11124/jbisrir-2012-5] [Reference Citation Analysis]
89 Bushra AW, Zeynudin A, Dejene T, Wolde M, Sudhakar M. Risk factors for tuberculosis after highly active antiretroviral treatment (HAART) initiation among HIV patients: A systematic review. JBI Libr Syst Rev 2012;10:3561-95. [PMID: 27819962 DOI: 10.11124/01938924-201210550-00001] [Reference Citation Analysis]
90 Kasprowicz VO, Churchyard G, Lawn SD, Squire SB, Lalvani A. Diagnosing latent tuberculosis in high-risk individuals: rising to the challenge in high-burden areas. J Infect Dis 2011;204 Suppl 4:S1168-78. [PMID: 21996699 DOI: 10.1093/infdis/jir449] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 2.9] [Reference Citation Analysis]
91 Lawn SD, Wood R. Tuberculosis in antiretroviral treatment services in resource-limited settings: addressing the challenges of screening and diagnosis. J Infect Dis 2011;204 Suppl 4:S1159-67. [PMID: 21996698 DOI: 10.1093/infdis/jir411] [Cited by in Crossref: 70] [Cited by in F6Publishing: 88] [Article Influence: 6.4] [Reference Citation Analysis]
92 Cingolani A, Cozzi Lepri A, Castagna A, Goletti D, De Luca A, Scarpellini P, Fanti I, Antinori A, d'Arminio Monforte A, Girardi E. Impaired CD4 T-Cell Count Response to Combined Antiretroviral Therapy in Antiretroviral-Naive HIV-Infected Patients Presenting With Tuberculosis as AIDS-Defining Condition. Clinical Infectious Diseases 2012;54:853-61. [DOI: 10.1093/cid/cir900] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
93 Lawn SD, Harries AD, Williams BG, Chaisson RE, Losina E, De Cock KM, Wood R. Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it? Int J Tuberc Lung Dis 2011;15:571-81. [PMID: 21756508 DOI: 10.5588/ijtld.10.0483] [Cited by in Crossref: 76] [Cited by in F6Publishing: 85] [Article Influence: 6.9] [Reference Citation Analysis]
94 Pettit AC, Jenkins CA, Stinnette SE, Rebeiro PF, Blackwell RB, Raffanti SP, Shepherd BE, Sterling TR. Tuberculosis risk before and after highly active antiretroviral therapy initiation: does HAART increase the short-term TB risk in a low incidence TB setting? J Acquir Immune Defic Syndr 2011;57:305-10. [PMID: 21423024 DOI: 10.1097/QAI.0b013e3182182e2d] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
95 Sterling TR, Lau B, Zhang J, Freeman A, Bosch RJ, Brooks JT, Deeks SG, French A, Gange S, Gebo KA, John Gill M, Horberg MA, Jacobson LP, Kirk GD, Kitahata MM, Klein MB, Martin JN, Rodriguez B, Silverberg MJ, Willig JH, Eron JJ, Goedert JJ, Hogg RS, Justice AC, McKaig RG, Napravnik S, Thorne J, Moore RD; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the International Epidemiologic Databases to Evaluate AIDS (IeDEA). Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening. J Infect Dis 2011;204:893-901. [PMID: 21849286 DOI: 10.1093/infdis/jir421] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
96 Date AA, Miller B. Antiretroviral therapy and tuberculosis: what's the connection and what's the way forward? J Acquir Immune Defic Syndr 2011;57:255-7. [PMID: 21602692 DOI: 10.1097/QAI.0b013e31822204fa] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
97 Kruk A, Bannister W, Podlekareva DN, Chentsova NP, Rakhmanova AG, Horban A, Domingo P, Mocroft A, Lundgren JD, Kirk O; EuroSIDA study group. Tuberculosis among HIV-positive patients across Europe: changes over time and risk factors. AIDS 2011;25:1505-13. [PMID: 21610489 DOI: 10.1097/QAD.0b013e328348fafd] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
98 Kwan CK, Ernst JD. HIV and tuberculosis: a deadly human syndemic. Clin Microbiol Rev. 2011;24:351-376. [PMID: 21482729 DOI: 10.1128/cmr.00042-10] [Cited by in Crossref: 391] [Cited by in F6Publishing: 427] [Article Influence: 35.5] [Reference Citation Analysis]
99 Marks SM, Magee E, Robison V. Patients diagnosed with tuberculosis at death or who died during therapy: association with the human immunodeficiency virus. Int J Tuberc Lung Dis 2011;15:465-70. [PMID: 21396204 DOI: 10.5588/ijtld.10.0259] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
100 Venkatesh KK, Swaminathan S, Andrews JR, Mayer KH. Tuberculosis and HIV Co-Infection: Screening and Treatment Strategies. Drugs 2011;71:1133-52. [DOI: 10.2165/11591360-000000000-00000] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
101 Taarnhøj GA, Engsig FN, Ravn P, Johansen IS, Larsen CS, Røge B, Andersen AB, Obel N. Incidence, risk factors and mortality of tuberculosis in Danish HIV patients 1995-2007. BMC Pulm Med 2011;11:26. [PMID: 21605366 DOI: 10.1186/1471-2466-11-26] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
102 Van Rie A, Westreich D, Sanne I. Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies. J Acquir Immune Defic Syndr 2011;56:349-55. [PMID: 20926954 DOI: 10.1097/QAI.0b013e3181f9fb39] [Cited by in Crossref: 64] [Cited by in F6Publishing: 71] [Article Influence: 5.8] [Reference Citation Analysis]
103 Middelkoop K, Bekker LG, Myer L, Johnson LF, Kloos M, Morrow C, Wood R. Antiretroviral therapy and TB notification rates in a high HIV prevalence South African community. J Acquir Immune Defic Syndr 2011;56:263-9. [PMID: 21317585 DOI: 10.1097/QAI.0b013e31820413b3] [Cited by in Crossref: 39] [Cited by in F6Publishing: 49] [Article Influence: 3.5] [Reference Citation Analysis]
104 Kipp AM, Desruisseau AJ, Qian HZ. Non-injection drug use and HIV disease progression in the era of combination antiretroviral therapy. J Subst Abuse Treat 2011;40:386-96. [PMID: 21353444 DOI: 10.1016/j.jsat.2011.01.001] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
105 D’Jaen GA, Pantanowitz L, Bower M, Buskin S, Neil N, Greco EM, Cooley TP, Henry D, Stem J, Dezube BJ. Human immunodeficiency virus-associated primary lung cancer in the era of highly active antiretroviral therapy: a multi-institutional collaboration. Clin Lung Cancer. 2010;11:396-404. [PMID: 21062730 DOI: 10.3816/clc.2010.n.051] [Cited by in Crossref: 49] [Cited by in F6Publishing: 56] [Article Influence: 4.5] [Reference Citation Analysis]
106 Straetemans M, Bierrenbach AL, Nagelkerke N, Glaziou P, van der Werf MJ. The effect of tuberculosis on mortality in HIV positive people: a meta-analysis. PLoS One 2010;5:e15241. [PMID: 21209936 DOI: 10.1371/journal.pone.0015241] [Cited by in Crossref: 30] [Cited by in F6Publishing: 37] [Article Influence: 2.5] [Reference Citation Analysis]
107 Piggott DA, Karakousis PC. Timing of antiretroviral therapy for HIV in the setting of TB treatment. Clin Dev Immunol 2011;2011:103917. [PMID: 21234380 DOI: 10.1155/2011/103917] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
108 Anandaiah A, Dheda K, Keane J, Koziel H, Moore DA, Patel NR. Novel developments in the epidemic of human immunodeficiency virus and tuberculosis coinfection. Am J Respir Crit Care Med 2011;183:987-97. [PMID: 21177884 DOI: 10.1164/rccm.201008-1246CI] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
109 Diaz A, Diez M, Bleda MJ, Aldamiz M, Camafort M, Camino X, Cepeda C, Costa A, Ferrero O, Geijo P, Iribarren JA, Moreno S, Moreno ME, Labarga P, Pinilla J, Portu J, Pulido F, Rosa C, Santamaría JM, Telenti M, Trapiella L, Trastoy M, Viciana P. Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain. BMC Infect Dis 2010;10:267. [PMID: 20840743 DOI: 10.1186/1471-2334-10-267] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
110 Blount RJ, Huang L. Clinical Approach to HIV-Associated Pulmonary Disease. Clinical Pulmonary Medicine 2010;17:210-217. [DOI: 10.1097/cpm.0b013e3181efa16f] [Reference Citation Analysis]
111 Biru T, Lennemann T, Stürmer M, Stephan C, Nisius G, Cinatl J, Staszewski S, Gürtler LG. Human immunodeficiency virus type-1 group M quasispecies evolution: diversity and divergence in patients co-infected with active tuberculosis. Med Microbiol Immunol 2010;199:323-32. [PMID: 20697741 DOI: 10.1007/s00430-010-0167-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
112 dos Santos RP, Deutschendorf C, Scheid K, Goldani LZ. In-hospital mortality of disseminated tuberculosis in patients infected with the human immunodeficiency virus. Clin Dev Immunol 2011;2011:120278. [PMID: 20811589 DOI: 10.1155/2011/120278] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
113 Lawn SD, Wood R, De Cock KM, Kranzer K, Lewis JJ, Churchyard GJ. Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. The Lancet Infectious Diseases 2010;10:489-98. [DOI: 10.1016/s1473-3099(10)70078-5] [Cited by in Crossref: 133] [Cited by in F6Publishing: 125] [Article Influence: 11.1] [Reference Citation Analysis]
114 Hanekom WA, Lawn SD, Dheda K, Whitelaw A. Tuberculosis research update. Trop Med Int Health 2010;15:981-9. [PMID: 20561306 DOI: 10.1111/j.1365-3156.2010.02568.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
115 Lazarous DG, O'Donnell AE. Pulmonary infections in the HIV-infected patient in the era of highly active antiretroviral therapy: an update. Curr Infect Dis Rep 2007;9:228-32. [PMID: 17430705 DOI: 10.1007/s11908-007-0036-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
116 Hermans SM, Kiragga AN, Schaefer P, Kambugu A, Hoepelman AI, Manabe YC. Incident tuberculosis during antiretroviral therapy contributes to suboptimal immune reconstitution in a large urban HIV clinic in sub-Saharan Africa. PLoS One 2010;5:e10527. [PMID: 20479873 DOI: 10.1371/journal.pone.0010527] [Cited by in Crossref: 59] [Cited by in F6Publishing: 63] [Article Influence: 4.9] [Reference Citation Analysis]
117 Abgrall S, Del Giudice P, Melica G, Costagliola D; FHDH-ANRS CO4. HIV-associated tuberculosis and immigration in a high-income country: incidence trends and risk factors in recent years. AIDS 2010;24:763-71. [PMID: 20087155 DOI: 10.1097/QAD.0b013e3283366747] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
118 Lawn SD, Kranzer K, Wood R. Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings. Clin Chest Med 2009;30:685-99, viii. [PMID: 19925961 DOI: 10.1016/j.ccm.2009.08.010] [Cited by in Crossref: 79] [Cited by in F6Publishing: 78] [Article Influence: 6.6] [Reference Citation Analysis]
119 Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010;CD000171. [PMID: 20091503 DOI: 10.1002/14651858.cd000171.pub3] [Cited by in Crossref: 128] [Cited by in F6Publishing: 280] [Article Influence: 10.7] [Reference Citation Analysis]
120 Levine DP, Brown PD. Infections in Injection Drug Users. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases 2010. [DOI: 10.1016/b978-0-443-06839-3.00316-7] [Reference Citation Analysis]
121 Olczak A, Grąbczewska E. Tuberculosis in HIV-infected patients in the HAART era. HIV & AIDS Review 2010;9:41-44. [DOI: 10.1016/s1730-1270(10)60068-9] [Reference Citation Analysis]
122 Etard JF, Diouf A, De Beaudrap P, Akoi K, Ngom-Guèye NF, Ndiaye I, Ecochard R, Sow PS, Eric D. Short and Long-Term Incidence of Tuberculosis and CD4-Cell Count Dynamic on HAART in Senegal. Open AIDS J 2009;3:63-70. [PMID: 20148061 DOI: 10.2174/1874613600903010063] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
123 Podlekareva DN, Mocroft A, Post FA, Riekstina V, Miro JM, Furrer H, Bruyand M, Panteleev AM, Rakhmanova AG, Girardi E, Losso MH, Toibaro JJ, Caylá J, Miller RF, Obel N, Skrahina A, Chentsova N, Lundgren JD, Kirk O; HIV/TB Study Writing Group. Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina. AIDS 2009;23:2485-95. [PMID: 19898216 DOI: 10.1097/QAD.0b013e3283326879] [Cited by in Crossref: 24] [Cited by in F6Publishing: 30] [Article Influence: 1.8] [Reference Citation Analysis]
124 Grant AD, Bansi L, Ainsworth J, Anderson J, Delpech V, Easterbrook P, Fisher M, Gazzard B, Gilson R, Gompels M, Hill T, Johnson M, Leen C, Orkin C, Phillips AN, Porter K, Post F, Walsh J, Sabin CA; United Kingdom Collaborative HIV Cohort Study Group. Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention? AIDS 2009;23:2507-15. [PMID: 19770622 DOI: 10.1097/QAD.0b013e3283320dfd] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 2.5] [Reference Citation Analysis]
125 Harmouche H, Ammouri W. [Tuberculosis and HIV coinfection]. Rev Med Interne 2009;30 Suppl 4:S273-6. [PMID: 19836110 DOI: 10.1016/j.revmed.2009.09.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
126 Lalvani A, Hingley-Wilson S. Editorial: Live or let die--does HIV exacerbate tuberculosis by attenuating M. tuberculosis-induced apoptosis? J Leukoc Biol 2009;86:9-11. [PMID: 19567412 DOI: 10.1189/JLB.0209075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
127 Mansoer J, Scheele S, Floyd K, Dye C, Sitienei J, Williams B. New methods for estimating the tuberculosis case detection rate in high-HIV prevalence countries: the example of Kenya. Bull World Health Organ 2009;87:186-92, 192A-B. [PMID: 19377714 DOI: 10.2471/blt.08.051474] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
128 Tseng SH, Shyong-Jiang DD, Hoi HS, Lo HY, Hwang KP. Effect of free treatment and surveillance on HIV-infected persons who have tuberculosis, Taiwan, 1993-2006. Emerg Infect Dis 2009;15:332-4. [PMID: 19193288 DOI: 10.3201/eid1502.081000] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
129 Lannoy LH, Cortez-Escalante JJ, Evangelista Mdo S, Romero GA. Tuberculosis incidence and risk factors among patients living with HIV/AIDS in public health service institutions in Brasilia, Federal District. Rev Soc Bras Med Trop 2008;41:549-55. [PMID: 19142430 DOI: 10.1590/s0037-86822008000600001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
130 Zhou J, Elliott J, Li PC, Lim PL, Kiertiburanakul S, Kumarasamy N, Merati TP, Pujari S, Chen YM, Phanuphak P, Vonthanak S, Sirisanthana T, Sungkanuparph S, Lee CK, Kamarulzaman A, Oka S, Zhang F, Tau G, Ditangco R. Risk and prognostic significance of tuberculosis in patients from The TREAT Asia HIV Observational Database. BMC Infect Dis 2009;9:46. [PMID: 19383122 DOI: 10.1186/1471-2334-9-46] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
131 Golub JE, Astemborski J, Ahmed M, Cronin W, Mehta SH, Kirk GD, Vlahov D, Chaisson RE. Long-term effectiveness of diagnosing and treating latent tuberculosis infection in a cohort of HIV-infected and at-risk injection drug users. J Acquir Immune Defic Syndr 2008;49:532-7. [PMID: 18989223 DOI: 10.1097/QAI.0b013e31818d5c1c] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
132 Manabe YC, Breen R, Perti T, Girardi E, Sterling TR. Unmasked tuberculosis and tuberculosis immune reconstitution inflammatory disease: a disease spectrum after initiation of antiretroviral therapy. J Infect Dis 2009;199:437-44. [PMID: 19090776 DOI: 10.1086/595985] [Cited by in Crossref: 62] [Cited by in F6Publishing: 64] [Article Influence: 4.8] [Reference Citation Analysis]
133 Chen W, Lin Y, Tsai W, Tsao Y. Unveiling tuberculous pyomyositis: an emerging role of immune reconstitution inflammatory syndrome. The American Journal of Emergency Medicine 2009;27:251.e1-2. [DOI: 10.1016/j.ajem.2008.05.030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
134 Deiss RG, Rodwell TC, Garfein RS. Tuberculosis and illicit drug use: review and update. Clin Infect Dis 2009;48:72-82. [PMID: 19046064 DOI: 10.1086/594126] [Cited by in Crossref: 121] [Cited by in F6Publishing: 129] [Article Influence: 9.3] [Reference Citation Analysis]
135 Velasco M, Castilla V, Cervero M, Sanz J, Condes E, Gaspar G, Torres R, Arranz A, Barros C, Monereo A; COMESEM cohort. The changing pattern of tuberculosis and HIV co-infection in immigrants and Spaniards in the last 20 years. HIV Med 2008;9:227-33. [PMID: 18366446 DOI: 10.1111/j.1468-1293.2008.00550.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
136 Sánchez MS, Lloyd-Smith JO, Porco TC, Williams BG, Borgdorff MW, Mansoer J, Salomon JA, Getz WM. Impact of HIV on novel therapies for tuberculosis control. AIDS 2008;22:963-72. [PMID: 18453856 DOI: 10.1097/QAD.0b013e3282f7cb4b] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
137 Lawn SD, Wilkinson RJ, Lipman MC, Wood R. Immune reconstitution and "unmasking" of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med 2008;177:680-5. [PMID: 18202347 DOI: 10.1164/rccm.200709-1311PP] [Cited by in Crossref: 140] [Cited by in F6Publishing: 155] [Article Influence: 10.0] [Reference Citation Analysis]
138 Maartens G, Wilkinson RJ. Tuberculosis. The Lancet 2007;370:2030-43. [DOI: 10.1016/s0140-6736(07)61262-8] [Cited by in Crossref: 216] [Cited by in F6Publishing: 234] [Article Influence: 14.4] [Reference Citation Analysis]
139 Muga R, Ferreros I, Langohr K, de Olalla PG, Del Romero J, Quintana M, Alastrue I, Belda J, Tor J, Pérez-Hoyos S, Del Amo J; Spanish Multicenter Study Group of Seroconverters (GEMES). Changes in the incidence of tuberculosis in a cohort of HIV-seroconverters before and after the introduction of HAART. AIDS 2007;21:2521-7. [PMID: 18025889 DOI: 10.1097/QAD.0b013e3282f1c933] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
140 Brinkhof MW, Egger M, Boulle A, May M, Hosseinipour M, Sprinz E, Braitstein P, Dabis F, Reiss P, Bangsberg DR, Rickenbach M, Miro JM, Myer L, Mocroft A, Nash D, Keiser O, Pascoe M, van der Borght S, Schechter M; Antiretroviral Therapy in Low-Income Countries Collaboration of the International epidemiological Databases to Evaluate AIDS (IeDEA)., ART Cohort Collaboration. Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clin Infect Dis 2007;45:1518-21. [PMID: 17990236 DOI: 10.1086/522986] [Cited by in Crossref: 76] [Cited by in F6Publishing: 81] [Article Influence: 5.1] [Reference Citation Analysis]
141 Vincenti D, Carrara S, Butera O, Bizzoni F, Casetti R, Girardi E, Goletti D. Response to region of difference 1 (RD1) epitopes in human immunodeficiency virus (HIV)-infected individuals enrolled with suspected active tuberculosis: a pilot study. Clin Exp Immunol 2007;150:91-8. [PMID: 17680823 DOI: 10.1111/j.1365-2249.2007.03462.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 48] [Article Influence: 2.8] [Reference Citation Analysis]
142 Mendonça M, Tanji MM, Silva LC, Silveira GG, Oliveira SC, Duarte AJ, Benard G. Deficient in vitro anti-mycobacterial immunity despite successful long-term highly active antiretroviral therapy in HIV-infected patients with past history of tuberculosis infection or disease. Clin Immunol 2007;125:60-6. [PMID: 17631053 DOI: 10.1016/j.clim.2007.06.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
143 Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, King BS, Efron A, Moore RD, Chaisson RE, Durovni B. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2007;21:1441-8. [PMID: 17589190 DOI: 10.1097/QAD.0b013e328216f441] [Cited by in Crossref: 196] [Cited by in F6Publishing: 222] [Article Influence: 13.1] [Reference Citation Analysis]
144 Park WB, Choe PG, Jo JH, Kim SH, Bang JH, Kim HB, Kim NJ, Oh MD, Choe KW. Tuberculosis manifested by immune reconstitution inflammatory syndrome during HAART. AIDS 2007;21:875-7. [PMID: 17415046 DOI: 10.1097/QAD.0b013e3280f7751f] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
145 Mathema B, Kurepina NE, Bifani PJ, Kreiswirth BN. Molecular epidemiology of tuberculosis: current insights. Clin Microbiol Rev 2006;19:658-85. [PMID: 17041139 DOI: 10.1128/CMR.00061-05] [Cited by in Crossref: 251] [Cited by in F6Publishing: 263] [Article Influence: 15.7] [Reference Citation Analysis]
146 Elzi L, Schlegel M, Weber R, Hirschel B, Cavassini M, Schmid P, Bernasconi E, Rickenbach M, Furrer H. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis. 2007;44:94-102. [PMID: 17143823 DOI: 10.1086/510080] [Cited by in Crossref: 79] [Cited by in F6Publishing: 83] [Article Influence: 4.9] [Reference Citation Analysis]
147 Verma S, Bhakta H, Nowain A, Kanel G, Squires K. Occult hepatic opportunistic infection (OI) and highly active antiretroviral therapy (HAART) induced immune reconstitution: an important cause of jaundice in a patient with AIDS. AIDS Res Hum Retroviruses 2006;22:1052-3. [PMID: 17067277 DOI: 10.1089/aid.2006.22.1052] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
148 Rockstroh JK, Hardy WD. Antiretroviral therapy in coinfected patients: viral hepatitis and tuberculosis. Curr Opin HIV AIDS 2006;1:442-8. [PMID: 19372845 DOI: 10.1097/01.COH.0000239858.30238.ff] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
149 Reid A, Scano F, Getahun H, Williams B, Dye C, Nunn P, De Cock KM, Hankins C, Miller B, Castro KG, Raviglione MC. Towards universal access to HIV prevention, treatment, care, and support: the role of tuberculosis/HIV collaboration. The Lancet Infectious Diseases 2006;6:483-95. [DOI: 10.1016/s1473-3099(06)70549-7] [Cited by in Crossref: 79] [Cited by in F6Publishing: 89] [Article Influence: 4.9] [Reference Citation Analysis]
150 Lawn SD, Badri M, Wood R. Risk factors for active tuberculosis among adults on highly active antiretroviral therapy in Africa: a reply. AIDS 2006;20:1463-5. [DOI: 10.1097/01.aids.0000233586.94961.06] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
151 Nahid P, Daley CL. Prevention of tuberculosis in HIV-infected patients. Curr Opin Infect Dis 2006;19:189-93. [PMID: 16514345 DOI: 10.1097/01.qco.0000216631.36316.62] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
152 Boyd AE, Bothamley GH. The Diagnosis of Latent Tuberculosis in HIV-Infected Persons. Clinical Infectious Diseases 2006;42:1498-1498. [DOI: 10.1086/503674] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
153 Franzetti F, Zanini F, Gazzola L, Codecasa L, Gori A. Molecular Epidemiology of Tuberculosis. Clinical Infectious Diseases 2006;42:1498-1499. [DOI: 10.1086/503683] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
154 Girardi E, Sabin CA, Monforte AD. Reply to Boyd and Bothamley and to Franzetti et al. Clinical Infectious Diseases 2006;42:1499-1500. [DOI: 10.1086/503676] [Reference Citation Analysis]
155 Lawn SD, Wood R. Incidence of tuberculosis during highly active antiretroviral therapy in high-income and low-income countries. Clin Infect Dis 2005;41:1783-6. [PMID: 16288404 DOI: 10.1086/498308] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 2.1] [Reference Citation Analysis]